Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 12/20 | 0.45 |
| ▸ | IDH2 | P48735 | 1/20 | 0.39 |
| ▸ | FABP4 | P15090 | 6/20 | 0.38 |
| ▸ | FABP5 | Q01469 | 6/20 | 0.38 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29676777 | 1.00 | IDH1 (0.45) | IDH1IDH2FABP4FABP5ATAD2 | |
| SCHEMBL20169018 | 0.90 | IDH1 (0.45) | IDH1IDH2FABP4FABP5 | |
| SCHEMBL31127027 | 0.88 | IDH1 (0.44) | IDH1IDH2FABP4FABP5ATAD2 | |
| SCHEMBL19686484 | 0.88 | IDH1 (0.44) | IDH1IDH2FABP4FABP5ATAD2 | |
| SCHEMBL21143747 | 0.87 | IDH1 (0.42) | IDH1IDH2FABP4FABP5ABCB1 | |
| SCHEMBL31127091 | 0.86 | IDH1 (0.49) | IDH1IDH2FABP4FABP5 | |
| SCHEMBL19686995 | 0.86 | IDH1 (0.49) | IDH1IDH2FABP4FABP5 | |
| SCHEMBL19686338 | 0.86 | IDH1 (0.51) | IDH1IDH2FABP4FABP5 | |
| SCHEMBL21165966 | 0.84 | IDH1 (0.49) | IDH1IDH2FABP4FABP5 | |
| SCHEMBL19686740 | 0.83 | IDH1 (0.41) | IDH1IDH2FABP4FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317705-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2024-09-26 | — | — | US | disclosed |
| CN-110198935-B | Potassium channel modulators | 卡登特治疗公司 | 2022-05-31 | — | — | CN | disclosed |
| US-20210380571-A1 | POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS INC (US) | 2021-12-09 | — | — | US | disclosed |
| EP-3571193-B1 | POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS INC (US) | 2021-12-01 | — | — | EP | disclosed |
| EP-3571193-B1 | POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS INC (US) | 2021-12-01 | — | — | EP | disclosed |
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10717728-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-07-21 | — | — | US | disclosed |
| US-10717728-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-07-21 | — | — | US | disclosed |
| US-20190352293-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-11-21 | — | — | US | disclosed |
| US-10351553-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2019-07-16 | — | — | US | disclosed |
| US-10351553-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2019-07-16 | — | — | US | disclosed |
| US-20180215746-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2018-08-02 | — | — | US | disclosed |
| US-20180215746-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2018-08-02 | — | — | US | disclosed |
| US-20180215746-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2018-08-02 | — | — | US | disclosed |
| WO-2018136917-A1 | POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS, INC. (US) | 2018-07-26 | — | — | WO | disclosed |
| US-9975886-B1 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-9975886-B1 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-9975886-B1 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| WO-2017139697-A9 | BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH HYPERAMMONEMIA | SYNLOGIC, INC. (US) | 2017-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317705-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | IDH1 3017/4885IDH2 2447/4885FABP4 2531/4885 |
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | IDH1 3017/4885IDH2 2447/4885FABP4 2531/4885 |
| US-20210380571-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNK10, KCNJ1 | IDH1 2868/4885IDH2 2185/4885FABP4 2595/4885 |
| US-10717728-B2 | Potassium channel modulators | KCNJ2, KCNQ2, KCNJ1 | IDH1 2691/4885IDH2 2021/4885FABP4 2121/4885 |
| US-20190352293-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNK10, KCNJ1 | IDH1 2868/4885IDH2 2185/4885FABP4 2595/4885 |
| US-20180215746-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNK10, KCNJ1 | IDH1 2868/4885IDH2 2185/4885FABP4 2595/4885 |
| US-10351553-B2 | Potassium channel modulators | KCNN2, KCNN1, KCNN3 | IDH1 3070/4885IDH2 2137/4885FABP4 2397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.